Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Cell Death Dis ; 15(2): 125, 2024 02 09.
Artigo em Inglês | MEDLINE | ID: mdl-38336839

RESUMO

Anaplastic thyroid carcinoma (ATC) has a 100% disease-specific mortality rate. The JAK1/2-STAT3 pathway presents a promising target for treating hematologic and solid tumors. However, it is unknown whether the JAK1/2-STAT3 pathway is activated in ATC, and the anti-cancer effects and the mechanism of action of its inhibitor, ruxolitinib (Ruxo, a clinical JAK1/2 inhibitor), remain elusive. Our data indicated that the JAK1/2-STAT3 signaling pathway is significantly upregulated in ATC tumor tissues than in normal thyroid and papillary thyroid cancer tissues. Apoptosis and GSDME-pyroptosis were observed in ATC cells following the in vitro and in vivo administration of Ruxo. Mechanistically, Ruxo suppresses the phosphorylation of STAT3, resulting in the repression of DRP1 transactivation and causing mitochondrial fission deficiency. This deficiency is essential for activating caspase 9/3-dependent apoptosis and GSDME-mediated pyroptosis within ATC cells. In conclusion, our findings indicate DRP1 is directly regulated and transactivated by STAT3; this exhibits a novel and crucial aspect of JAK1/2-STAT3 on the regulation of mitochondrial dynamics. In ATC, the transcriptional inhibition of DRP1 by Ruxo hampered mitochondrial division and triggered apoptosis and GSDME-pyroptosis through caspase 9/3-dependent mechanisms. These results provide compelling evidence for the potential therapeutic effectiveness of Ruxo in treating ATC.


Assuntos
Nitrilas , Pirazóis , Pirimidinas , Carcinoma Anaplásico da Tireoide , Neoplasias da Glândula Tireoide , Humanos , Carcinoma Anaplásico da Tireoide/tratamento farmacológico , Carcinoma Anaplásico da Tireoide/genética , Carcinoma Anaplásico da Tireoide/metabolismo , Neoplasias da Glândula Tireoide/tratamento farmacológico , Neoplasias da Glândula Tireoide/genética , Neoplasias da Glândula Tireoide/metabolismo , Dinâmica Mitocondrial , Piroptose , Caspase 9/metabolismo , Proliferação de Células , Linhagem Celular Tumoral , Apoptose
2.
BMC Neurosci ; 15: 84, 2014 Jul 02.
Artigo em Inglês | MEDLINE | ID: mdl-24985061

RESUMO

BACKGROUND: During the clinical treatment of the brachial plexus root avulsion (BPRA), reimplantation surgery can not completely repair the motor function of the hand because the axonal growth velocity of the spinal motoneurons (MNs) is too slow to re-innervate the intrinsic hand muscles before muscle atrophy. Here, we investigated whether lithium can enhance the regenerative capacity of the spinal MNs in a rat model of BPRA. RESULTS: The avulsion and immediate reimplantation of the C7 and C8 ventral roots were performed and followed with daily intraperitoneal administration of a therapeutic concentrationof LiCl. After a 20 week long-term rehabilitation, the motor function recovery of the injured forepaw was studied by a grasping test. The survival and regeneration of MNs were checked by choline acetyltransferase (ChAT) immunofluorescence and by Fluoro-Gold (FG) retrograde labeling through the median and ulnar nerves of the ventral horn MNs. The number and diameter of the nerve fibers in the median nerve were assessed by toluidine blue staining. Our results showed that lithium plus reimplantation therapy resulted in a significantly higher grasping strength of the digits of the injured forepaw. Lithium plus reimplantation allowed 45.1% ± 8.11% of ChAT-positive MNs to survive the injury and increased the number and diameter of nerve fibers in the median nerve. The number of FG-labeled regenerative MNs was significantly elevated in all of the reimplantation animals. Our present data proved that lithium can enhance the regenerative capacity of spinal MNs. CONCLUSIONS: These results suggest that immediate administration of lithium could be used to assist reimplantation surgery in repairing BPRA injuries in clinical treatment.


Assuntos
Cloreto de Lítio/farmacologia , Neurônios Motores/efeitos dos fármacos , Regeneração Nervosa/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Radiculopatia/terapia , Medula Espinal/efeitos dos fármacos , Animais , Axônios/efeitos dos fármacos , Axônios/patologia , Axônios/fisiologia , Plexo Braquial/efeitos dos fármacos , Plexo Braquial/fisiopatologia , Sobrevivência Celular/efeitos dos fármacos , Sobrevivência Celular/fisiologia , Vértebras Cervicais , Modelos Animais de Doenças , Membro Anterior/fisiopatologia , Masculino , Microcirurgia/métodos , Atividade Motora/efeitos dos fármacos , Atividade Motora/fisiologia , Neurônios Motores/patologia , Neurônios Motores/fisiologia , Regeneração Nervosa/fisiologia , Procedimentos Neurocirúrgicos , Radiculopatia/patologia , Radiculopatia/fisiopatologia , Radiculopatia/reabilitação , Distribuição Aleatória , Ratos Sprague-Dawley , Recuperação de Função Fisiológica/efeitos dos fármacos , Recuperação de Função Fisiológica/fisiologia , Reimplante/métodos , Medula Espinal/patologia , Medula Espinal/fisiopatologia
3.
Int J Clin Pharmacol Ther ; 51(4): 332-7, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23380427

RESUMO

OBJECTIVE: Bone marrow mesenchymal stem cell (BMSC) is a potentially effective vehicle for the cell and gene therapy in clinical disease treatment. We studied whether the most commonly used anesthetic drugs have negative effects on rat BMSCs in vitro. MATERIALS AND METHODS: The cultured BMSCs were treated with sevoflurane (in 1.7%, 2.3%, and 3%); propofol (5 µg/ml, 10 µg/ml and 20 µg/ml); or 2.3% sevoflurane plus 10 µg/ml propofol. After 4-hour treatment, the cultured BMSCs were prepared for MTT reduction assays and cell morphology observation. RESULTS: Compared to the controls, the 4-hour sevoflurane exposure resulted in decreased cell viability of BMSCs in a concentration-dependent manner; however, 1.7% sevoflurane did not reduce the cell viability. The 4-hour propofol treatment did not affect the cell viability; but combined usage of 2.3% sevoflurane and 10 µg/ml propofol decreased cell viability. In BMSCs treated with higher concentration of sevoflurane (1.7% and 2.3%) and combined usage of the two anesthetics, the cell became raritas with wizened cytoplasm and had fewer connections to each other of BMSCs. More than 2.3%, or 2.3% sevoflurane plus 10 µg/ ml propofol caused cytotoxicity to BMSCs. However, propofol up to 20 µg/ml did not harm the BMSCs. CONCLUSIONS: The study indicates that it is necessary to choose the right anesthesia during the BMSCs transplantation therapy.


Assuntos
Anestésicos Combinados/toxicidade , Células-Tronco Mesenquimais/efeitos dos fármacos , Éteres Metílicos/toxicidade , Propofol/toxicidade , Anestésicos Combinados/administração & dosagem , Anestésicos Inalatórios/administração & dosagem , Anestésicos Inalatórios/toxicidade , Anestésicos Intravenosos/administração & dosagem , Anestésicos Intravenosos/toxicidade , Animais , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Relação Dose-Resposta a Droga , Células-Tronco Mesenquimais/metabolismo , Éteres Metílicos/administração & dosagem , Propofol/administração & dosagem , Ratos , Ratos Sprague-Dawley , Sevoflurano
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA